Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Secord, AA, McCollum, M, Davidson, BA, Broadwater, G, Squatrito, R, Havrilesky, LJ, Gabel, AC, Starr, MD, Brady, JC, Nixon, AB, and Duska, LR. "Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer." Gynecologic Oncology (March 28, 2019).

PMID
30929823
Full Text

Mettu, NB, Niedzwiecki, D, Rushing, C, Nixon, AB, Jia, J, Haley, S, Honeycutt, W, Hurwitz, H, Bendell, JC, and Uronis, H. "A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors." March 20, 2019.

PMID
30895346
Full Text

Innocenti, F, Jiang, C, Sibley, AB, Denning, S, Etheridge, AS, Watson, D, Niedzwiecki, D, Hatch, AJ, Hurwitz, HI, Nixon, AB, Furukawa, Y, Kubo, M, Crona, DJ, Kindler, HL, McLeod, HL, Ratain, MJ, and Owzar, K. "An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients CALGB 80303 (Alliance)." Pharmacogenetics and Genomics (March 18, 2019).

PMID
30889042
Full Text

Kelly, FL, Weinberg, KE, Nagler, AE, Nixon, AB, Star, MD, Todd, JL, Brass, DM, and Palmer, SM. "EGFR-dependent IL8 Production by Airway Epithelial Cells after Exposure to the Food Flavoring Chemical 2,3-butanedione." Toxicological Sciences : an Official Journal of the Society of Toxicology (March 9, 2019).

PMID
30851105
Full Text

Hsi, ED, Li, H, Nixon, AB, Schöder, H, Bartlett, NL, LeBlanc, M, Smith, S, Kahl, BS, Leonard, JP, Evens, AM, Scott, DW, Rimsza, LM, and Friedberg, JW. "Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study." Blood (February 5, 2019).

PMID
30723079
Full Text

Choueiri, TK, Michaelson, MD, Posadas, EM, Sonpavde, GP, McDermott, DF, Nixon, AB, Liu, Y, Yuan, Z, Seon, BK, Walsh, M, Jivani, MA, Adams, BJ, and Theuer, CP. "An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma." The Oncologist 24, no. 2 (February 2019): 202-210.

PMID
30190302
Full Text

Innocenti, F, Jiang, C, Sibley, AB, Etheridge, AS, Hatch, AJ, Denning, S, Niedzwiecki, D, Shterev, ID, Lin, J, Furukawa, Y, Kubo, M, Kindler, HL, Auman, JT, Venook, AP, Hurwitz, HI, McLeod, HL, Ratain, MJ, Gordan, R, Nixon, AB, and Owzar, K. "Genetic variation determines VEGF-A plasma levels in cancer patients." Scientific Reports 8, no. 1 (November 5, 2018): 16332-null.

PMID
30397360
Full Text

Melosky, B, Reardon, DA, Nixon, AB, Subramanian, J, Bair, AH, and Jacobs, I. "Bevacizumab biosimilars: scientific justification for extrapolation of indications." Future Oncology (London, England) 14, no. 24 (October 2018): 2507-2520. (Review)

PMID
29690784
Full Text

Liu, Y, Starr, MD, Brady, JC, Rushing, C, Pang, H, Adams, B, Alvarez, D, Theuer, CP, Hurwitz, HI, and Nixon, AB. "Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105." Molecular Cancer Therapeutics 17, no. 10 (October 2018): 2248-2256.

PMID
29997150
Full Text

Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.

PMID
29572245
Full Text

Pages